How CBD affects immune cells in severe lung inflammation caused by a virus
Role of Macrophages in CBD mediated attenuation of SEB-induced ARDS
This study is looking at how a substance called Cannabidiol (CBD) might help improve survival in people with severe lung inflammation, like what happens in serious cases of COVID-19, by reducing inflammation and protecting lung cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Carolina at Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10901972 on NIH RePORTER |
What this research studies
This research investigates the role of macrophages in the inflammatory response associated with Acute Respiratory Distress Syndrome (ARDS) induced by Staphylococcus enterotoxin B (SEB), which mimics severe COVID-19. The study explores how Cannabidiol (CBD) treatment can improve survival rates in a mouse model of ARDS by reducing inflammation and protecting lung cells. By analyzing immune cell responses and cytokine levels, the research aims to uncover the mechanisms through which CBD may provide therapeutic benefits for patients suffering from severe lung inflammation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing severe respiratory distress or ARDS, especially those affected by COVID-19.
Not a fit: Patients with mild respiratory symptoms or those not experiencing significant inflammation in the lungs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with severe respiratory conditions, particularly those related to COVID-19.
How similar studies have performed: Previous research has shown promising results with CBD in reducing inflammation, suggesting potential for success in this novel application.
Where this research is happening
Columbia, United States
- University of South Carolina at Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Wilson, Kiesha — University of South Carolina at Columbia
- Study coordinator: Wilson, Kiesha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.